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ORIGINAL RESEARCH
NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL- 
10 phenotype
Francesca Marcona*, Jianmin Zuob*, Hayden Pearceb, Samantha Nicolb, Sandra Margielewska-Daviesb, Mustafa Farhatb, 
Brinder Mahona, Gary Middletonb, Rachel Browna, Keith J. Robertsa*, and Paul Mossb*
aUniversity Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham,, Birmingham;UK; bInstitute of Immunology and 
Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and remains 
associated with very poor survival. T cell infiltration into tumor tissue is associated with improved clinical 
outcome but little is known regarding the potential role of NK cells in disease control. Here we analyze the 
phenotype and function of NK cells in the blood and tumor tissue from patients with PDAC. Peripheral NK 
cells are present in normal numbers but display a CD16hiCD57hi phenotype with marked downregulation 
of NKG2D. Importantly, these cells demonstrate reduced cytotoxic activity and low levels of IFN-γ 
expression but instead produce high levels of intracellular IL-10, an immunoregulatory cytokine found 
at increased levels in the blood of PDAC patients. In contrast, NK cells are largely excluded from tumor 
tissue where they display strong downregulation of both CD16 and CD57, a phenotype that was 
recapitulated in primary NK cells following co-culture with PDAC organoids. Moreover, expression of 
activatory proteins, including DNAM-1 and NKP30, was markedly suppressed and the DNAM-1 ligand PVR 
was strongly expressed on tumor cells. As such, in situ and peripheral NK cells display differential features 
in patients with PDAC and indicate local and systemic mechanisms by which the tumor can evade 
immune control. These findings offer a number of potential options for NK-based immunotherapy in 
the management of patients with PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) incidence is rising 
and remains associated with a 5 year survival rate of less than 5% 
with virtually no improvement in clinical outcome over the last 
10 years.1–4 Indeed, current predictions suggest that PDAC may 
become the second most common cause of cancer death by 
2030.5 Chemotherapy and radiotherapy-based regimens are cur-
rently limited and there is interest in developing novel forms of 
immunotherapy. Patients with PDAC display poor responses to 
checkpoint inhibition6 and there is thus a clear need to better 
understand the mechanisms of immune evasion.
The microenvironment of pancreatic ductal adenocarcinoma 
is typically characterized by extreme hypoxia and a dense stromal 
‘desmoplastic’ reaction (TME)7 which together act to support 
tumor progression, metastasis, and chemoresistance.8–10 
Features of immune suppression, such as elevated serum and 
tissue levels of IL-10 and TGF-β, have been observed.11–13 
Despite this, an immune infiltrate is present within many tumors 
and has been associated with improved clinical outcome.14–17 
Indeed, although immune cells typically demonstrate an 
exhausted phenotype in situ12 they can be expanded in vitro to 
recognize autologous tumor cells.18
In contrast, the phenotypic and functional features of Natural 
Killer (NK) cells within the PDAC microenvironment has been 
less intensively investigated although NK cells exhibit impaired 
killing of autologous PDAC cells due to NKG2D and DNAM-1 
deficiency19 and an increased number of peripheral NK cells 
may act as a prognostic marker for longer recurrence-free survi-
val and overall survival.20,21 NK cells play an important role in 
controlling the development of cancer22–24 through loss of inhi-
bitory signaling from cells with downregulation of HLA25 and 
activatory engagement with ‘stress’ molecules such as NKG2D 
ligands.26–28 The ultimate outcome of NK cell engagement with 
a target cell is mediated through the balance of inhibitory and 
activatory interactions and there is now considerable interest in 
understanding both how tumor cells evade NK cell recognition 
and if they may be exploited for immunotherapy.29 Here we 
determined the phenotypic and functional profile of NK cells 
from patients undergoing surgical resection of PDAC tumors. 
We show that a range of mechanisms of immune evasion are 
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Queen Elizabeth Hospital Birmingham over 3-years period 
(2016–2019) under appropriate ethical approval (REC no 16/ 
WM/0214). Samples from 34 healthy age-matched donors were 
also obtained. Patients were selected who had localized disease, 
without local invasion or metastasis, and who were undergoing 
Whipple’s resection with curative intent.
Immunophenotyping
25 ml of blood was collected prior to pancreaticoduode-
nectomy surgery and peripheral blood mononuclear cell 
(PBMC) were collected by density centrifugation. After 
defrosting, PBMCs were washed and re-suspended at 
106cells/100 μl before staining with one of the following 
antibody panels. Panel 1; anti-DNAM-1 FITC (11A8 
Biolegend) (5 µl); anti-PD-1 PE (EH12.2 H Biolegend) 
(3ul); anti-CD14/CD19 PE dazzle (HCD14/H1B19 
Biolegend) (1.5 µl/2.5 µl); anti-NKp46 PerCP/Cy5.5 
(Biolegend) (5 µl); anti-CD56 PEcy7(HCD56 Biolegend) 
(3 µl); anti-NKG2D APC (BD Biosciences) (5 µl); anti- 
CD3 AF700 (HIT3a Biolegend) (2.5 µl) and anti-CD16 
Pacific Blue (3G8 Biolegend) (5 µl). Panel 2; anti-NKG2C 
FITC(11A8Milteny Biotec) (2µl); anti-CD94 PE (DX22 
Biolegend)(1 µl); anti-CD14/CD19 PE-dazzle (HCD14/ 
H1B19Biolegend) (1.5 µl/2.5 µl); anti-KIRS PerCP/Cy5.5 
(HP-MA4 Biolegend)(5 µl); anti-CD56PECy7 (HCD56 
Biolegend) (3 µl); anti-NKp30 APC (Biolegend)(5 µl); 
anti-CD3 AF700 (HIT3a Biolegend) (2.5 µl) and anti- 
CD57 Pacific Blue (HNK-1Biolegend) (3 µl).
Antibody stained samples were run on a BC Gallios 
flow cytometer within 1 h of staining. At least 100,000 
events were acquired per sample using CytoSoftware, and 
analyzed offline using Kaluza v1.5 software.
Isolation of Tumor-infiltrating lymphocytes (TIL)
Tumor was cut into 1–2 mm pieces and incubated over-
night in tissue media culture (RPMI 1640 + 10% FCS+1% 
Penicillin/Streptomicin+1% L-Glutamine) to allow TILs to 
migrate out of tissue. Media was spun at 1600 rpm for 
5 min prior to flow cytometric analysis.
NK cell cytotoxicity assay
NK cells were enriched using EasySep™ Human NK cell 
enrichment kit (Stem Cell Technologies, Canada) and 
activated overnight at with IFNα (sigma, 10 ng/ml)., 
K562 cells were labeled with CFSE and co-cultured with 
the pre-activated NK cells at E:T ratio of 1:1. Cells were 
co-cultured for 16 hours prior to analysis using BD 
Accuri™ flow cytometer (BD Bioscience) and specific lysis 
calculated on live cell enumeration.27 The equation for 
calculation is: 100 × (1 – [(experimental group cell 
count)/(control cell count)]).
Intracellular cytokine staining
PBMCs and K562 were co-cultured overnight with Brefeldin 
A (SIGMA ALDRICH) (1 µl/ml) at 1:1 ratio. Co-cultures were 
washed and stained with appropriate surface antibodies and PB 
live/dead dye (Invitrogen; Massachusetts, USA) before the 
fixation and permeabilization. Cells were then stained with 
antibodies against intracellular cytokines, washed, and ana-
lyzed using flow cytometry.
Quantitative reverse-transcription polymerase chain 
reaction (qRT-PCR)
Total RNA was isolated from normal pancreatic tissues 
and tumor tissues using QIAGEN RNeasy kit and treated 
with DNase I (Turbo DNA-free kit; Ambion). Q-RT-PCR 
assays were performed with TaqMan® Gene Expression 
Assays (Applied Biosystems), reference plasmids contain-
ing relevant target gene sequences were used to generate 
standard curves.
Immunohistochemistry
10 cases of paraffin wax embedded PDAC Tissue sections 
were de waxed and re-hydrated. Endogenous peroxidase 
activity was blocked using 0.3% H2O2 and the citrate 
buffer antigen retrieval method was performed. Before 
application of primary antibodies, slides were blocked in 
5x casein (Vector Laboratories Ltd.). Primary antibodies 
Anti-ULBP2 (ab88645; Abcam) and Anti-PVR 
(HPA012568; Atlas Antibodies) were diluted in PBS to 
desired concentration. For visualization of staining DAB 
substrate was added (Vector Laboratories Ltd). Stained 
tissue was analyzed under the Eclipse E400 microscope 
(Nikon) and images were taken with 40x magnification.
Co-culture of organoid and autologous PBMCs
Tumor was diced into approximately 2 mm sections and 
crushed with the butt of a syringe. Homogenate was poured 
into basal culture media containing Type II Collagenase 
(Life Technologies; [2.5 mg/mL]) and shaken at 37°C for 
60 min prior to dilution with basal culture medium and 
filtration through a 70uM filter (Falcon Catalog number 
352350). The cell suspension was pelleted and washed 
prior to incubation with growth factor-reduced Matrigel 
(Corning Catalog number CB-40230 C), with final concen-
tration at 75%. The suspension was then rapidly plated into 
a 24-well plate with 50uL of suspension per well. 20 min 
later, 600uL of general culture medium was added to each 
well of the solidified Matrigel. General culture medium was 
composed of Advanced DMEM/F12, supplemented with 1% 
penicillin streptomycin, 1X Glutamax, 1% HEPES, 100 ng/ 
mL R-spondin 1 (Peprotech catalog number 120–38), 
100 ng/mL Noggin (Peprotech catalog number 120–10 C), 
50 ng/mL EGF (Peprotech catalog number 100–15), 10 ng/ 
mL FGF-10 (Peprotech catalog number 100–26), 10 ng/mL 
FGF2 (Peprotech catalog number 100–18B), 1x B27 (Life 
Technologies Catalog number 17504044), 10 mM 
Nicotinamide (Sigma Aldrich Catalog Number N0636), 
1.25 mM N-acetylcysteine (Sigma Aldrich catalog number 
A9165), 1uM Prostaglandin E2 (Catalog number R&D 
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Systems Catalog number 2296), 10uM SB202190 (Sigma 
Aldrich Catalog number S7076), and 500 nm A83-01 
(Sigma Aldrich catalog number SML0788). Medium was 
replaced every 3–4 days and matured organoids passaged 
1:3 every 14 days. Autologous PBMC were defrosted and 
cultured in vitro, with or without organoid, with IL-2 added 
after 3 days at 200IU/ml. Co-cultures were maintained for 
7–14 days prior to immuno-phenotyping.
Statistical analysis
Statistical analysis was performed with SPSS 24 and Prism 
8. Each parameter was checked for normal distribution. 
A paired-t or the related samples-Wilcoxon Signed Rank 
test for non-parametric variables were used accordingly. 
A p value <.05 was considered statistical significant. The 
clinical correlation was carried out using Spearman’s Rank 
correlation test. Also the effect of NK cell on overall 
survival, disease-free survival, and recurrence were plotted 
using the Kaplan–Meier method and assessed with the log- 
rank (Mantel-Cox) method.
Results
Patients with PDAC have normal numbers of NK cells 
within blood but expression of CD16 is increased on the 
CD56dim subset
The overall percentage of NK cells within the blood of patients 
with PDAC was not reduced and comprised 18% of PBMC 
compared to 16% in healthy donors (p = .52) (Figure 1b). The 
relative distribution of NK cells within major NK subsets was 
then examined by analysis of CD16 and CD56 expression. 
These four major subsets comprise CD56dimCD16bright, 
CD56brightCD16negative, CD56brightCD16bright and 
CD56dimCD16negative subgroups30 (Figure 1a). As anticipated, 
CD56dimCD16bright cells were the dominant population in 
healthy donors, representing 79% of NK cells, with values of 
6.4, 2.2, and 12% for CD56brightCD16negative, CD56bright 
CD16bright and CD56dimCD16negative cells, respectively (Figure 
1c+1d). Interestingly, the CD56dimCD16bright population was 
further increased in the blood of PDAC patients where it 
comprised 87% of total cells (p = .001). The 
CD56brightCD16negative, CD56bright CD16bright and 
CD56dimCD16negative subsets were measured at 4.2, 1.9, and 
Figure 1. Patients with PDAC have normal numbers of NK cells within blood but expression of CD16 is increased on the CD56dim subset. (A): Left panel: An example of 
dot plot from flow cytometry staining to gate the NK cells using CD3- CD56+ as the makers. Right panel: An example of dot plot to gate the four NK subsets according to 
CD56 and CD16 expression, CD56dimCD16bright, CD56bright CD16bright, CD56dimCD16negative and CD56brightCD16negative NK cells. (B): The percentage of CD3- CD56+ NK 
cells out of PBMCs were compared between PDAC patients and healthy donors using violin plot with each point represent a donor. (C): The composition of these four NK 
subsets in the bloods from PDAC patients and HDs were compared in bar chart. (D): Percentage of four NK subsets in the bloods from PDAC patients and HDs were 
compared individually using violin plot with each point represent a donor with significance was determined using Mann-Whitney testing, p< .01(**) and p<.0001(***).
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6.7%, respectively (Figure 1c right panel and 1D), representing 
a 44% reduction of CD56dimCD16negative cells within the 
patient group (p = .0001).
Peripheral NK cells from PDAC patients express reduced 
levels of the activating receptors NKG2D and NKp30
We next went on to assess the expression of markers associated 
with NK cell differentiation and activation on peripheral NK 
cells. CD57 expression is expressed on late differentiated cells 
and associated with high cytotoxic activity.31 Of note, CD57 
was expressed on 50% of cells in the patient group compared to 
only 44% within healthy donors (p = .04) (Figure 2a). The 
major activatory protein CD16 was also increased in patients, 
expressed on 88% compared to 77% of controls (p = .0002) 
(Figure 2a). A trend toward increased expression of NKG2C 
(Figure 2a) was also seen in the patient group (NKG2C: 4.8% vs 
5.2% for HD vs PDAC, p = .68). Overall this profile reveals 
Figure 2. Peripheral NK cells from PDAC patients express reduced levels of the activating receptors NKG2D and NKp30. The expression of differentiation markers 
including CD16, CD57, NKG2C(A) and activatory makers including DNAM-1. NKG2D, NKp30 (B) were compared between PDAC patients and HDs. The left panel of each 
marker is the histogram of representative examples to show the expression of each marker in PDAC patients and HDs. The comparison was carried out with percentage 
(middle panel) and mean florescence intensity (MFI) (right panel).The significance was determined using Mann-Whitney testing, p< .05(*), p< .01(**) and p< .001(***).
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a somewhat more differentiated profile of peripheral NK cells 
within the patient group.
Activating receptors are critical regulators of NK cell activity 
and are frequently downregulated in the setting of cancer. We 
next defined the expression of the major activatory receptors 
NKG2D, DNAM-1 and NKp30. NKG2D expression was down-
regulated in the patient group, present on 51% of cells compared 
to 66% of healthy donors (p = .027) (Figure 2b). The mean 
florescence intensity (MFI) of expression was also lower at 
3200 ± 564 and 4620 ± 525, respectively (p= .047). NKp30 
expression was also reduced, present on 47% and 66% of cells 
in PDAC patients and controls, respectively (p= .023) (Figure 
2b). In contrast, expression of DNAM-1 did not differ between 
the two groups, present on 79% of cells in both cohorts 
(Figure 2b).
NK cells within the blood of PDAC patients have reduced 
cytotoxic function and express high levels of IL-10
The functional capacity of NK populations was next assessed by 
assessment of relative cytotoxic activity and the pattern of cytokine 
production. Cytokine production was assessed by incubation of 
PBMC with K562 prior to assessment of cytokine production using 
intracellular staining. NK cells normally produce substantial 
amounts of proinflammatory cytokine such as IFN-γ and TNF-α 
and this pattern was observed in healthy donors. However, IFN-γ 
production was substantially reduced in NK cells from PDAC 
patients (1.9% vs. 5.1% in controls; p= .003) (Figure 3a) and atrend 
toward reduced levels of TNF-α was also seen (2.4% vs 3.9%, 
p= .12) (Figure 3b left panel). IL-2 production was also lower in 
the patient group, present within only 0.7% of cells compared to 
2.4% from healthy donors (p= .009) (Figure 3a). Strikingly, IL-10 
production was markedly increased in NK cells from PDAC 
patients, present in 9.8% of cells compared to only 2.2% in healthy 
donors (p= .001) (Figure 3a). Expression of IL-4 and IL-5 was 
comparable between donors (Figure 3b middle and right panel). 
Lytic activity of NK cells was analyzed on K562 target cells and 
cytotoxicity was markedly reduced compared to healthy donors 
(42% vs. 70%, respectively, at E:T ratio 1:1 (p= .026) (Figure 3c).
NK cells are a minority population within PDAC tumors 
and show strong downregulation of CD16
Having observed substantial differences in the phenotype 
and function of NK cells in the blood of PDAC patients 
we next went on to assess the phenotype of NK cells 
isolated from the tumor microenvironment using 9 paired 
samples of blood (PBMC-NK) and tumor-infiltrating lym-
phocytes (TIL-NK).
The percentage of NK cells was markedly suppressed within TIL 
populations, representing only 3.5% of cells compared to 17% 
within PBMC (p= .005) (Figure 4a and 4b). The relative 
Figure 3. NK cells within the blood of PDAC patients have reduced cytotoxic function and express high levels of IL-10. (A and B): Whole PBMCs from PDAC patients and 
HDs were co-cultured with K562 cells at 1:1 ratio in the presence of Brefeldin A for overnight before the cells were stained for surface receptors, fixed permeabilised and 
stained with IFN-γ, IL-2, IL-10, TNF-α, IL-4 and IL-5 antibodies. The percentage of NK cells that produce each cytokine was compared between PDAC patients and HDs. 
Each plot represents one cytokine. (C) NK cells were enriched and co-cultured with CFSE labeled K562 cells for 16hrs. The cytotoxicity was calculated according to the 
relative cell count of the live populations of target cells using flow cytometry. Data shown are as violin plots with each dot represents adonor. The significance was 
determined using Mann-Whitney testing, p< .05(*) and p< .01(**).
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distribution of TIL-NK and PBMC-NK within the four major NK 
subsets was then defined by CD16 and CD56 expression. Of note, 
the dominant phenotype of TIL-NK cells was the 
CD56dimCD16negative population which comprised 55% of the 
total pool. CD56dimCD16bright, CD56brightCD16negative and 
CD56bright CD16bright subgroups represented 22, 21, and 2.2%, 
respectively, of the remaining population (Figure 4d). This was a 
substantially different profile from that seen within PBMC-NK 
where, as expected, 89% of cells expressed aCD56dimCD16bright 
phenotype. CD56brightCD16negative, CD56bright CD16bright and 
CD56dimCD16negative cells also comprised 4%, 2.2% and 4.6%, 
respectively (Figure 4d). As such these findings show a marked 
downregulation of CD16 within the tumor microenvironment, 
which was present on only 27% of total TIL-NK compared to 
92% of PBMC-NK (p< .0001) (Figure 5a).
Expression of activatory receptors is reduced substantially 
on NK cells within the PDAC tumor
The extended phenotype of TIL-NK was then assessed 
using flow cytometry. CD57 expression was seen to be 
very low, present on 11% of cells compared to 44% in 
blood (p= .0001; Figure 5a) . This data from CD16 and 
CD57 suggests aless differentiated phenotype for TIL-NK 
populations. But interestingly, NKG2C expression was 
marginally increased at 9.2% compared to 6.1% on PBMC- 
NK (p = .04).
Strikingly, downregulation of NK activatory receptors was pro-
foundly suppressed on TIL-NK cells, further extending the profile 
that had been observed in PBMC-TIL populations. This was seen 
most clearly in both the percentage and median fluorescent inten-
sity (MFI) of DNAM-1 and NKp30 expression. DNAM-1 was 
present on only 32% of TIL-NK cells compared to 83% of PBMC- 
NK (p< .0001) (Figure 5b) with NKp30 expression of 26% and 60%, 
respectively (p= .007) (Figure 5b). Relative MFI values were 
1430 ± 214 and 4860 ± 294 for DNAM-1 and 2860 ± 475 and 
7120 ± 1308 for NKp30, respectively (Figure 5b).
Although NKG2D expression had been seen to be reduced on 
peripheral NK cells from PDAC patients, this remained stable 
within the TIL populations with no further reduction (48% versus 
58% in TIL-NK and PBMC-NK, respectively; p= .15) (Figure 5b).
The PDAC tumor microenvironment expresses high levels 
of NK cell ligands and tumors induce downregulation of 
CD16 and CD57 on NK cells
In order to interrogate mechanisms that might lead to the 
characteristic phenotype of NK cells within PDAC tumors 
Figure 4. NK cells are a minority population within PDAC tumors and show strong downregulation of CD16. (A): Examples of dot plot from flow cytometry staining to 
gate the NK cells using CD3- CD56+ as the makers with left panel represents PBMCs and right panel represents TILs from PDAC patient. (B) The percentage of CD3- CD56 
+ NK cells were compared between PBMCs and TILs from PDAC patients with each point represent a donor. (C) Examples of dot plots to gate the four NK subsets 
according to CD56 and CD16 expression, CD56dimCD16bright, CD56bright CD16bright, CD56dimCD16negative and CD56brightCD16negative NK cells. The left panel represents 
PBMCs and right panel represents TILs from PDAC patient. (D): The composition of these four NK subsets in PBMC and TILs from PDAC patients were compared in bar 
chart. (D): Percentage of four NK subsets in the PBMCs and TILs from PDAC patients were compared individually with each point represent a donor with significance was 
determined using Wilcoxon matched-pairs signed rank test, P< .01(**).
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we next examined the expression of ligands for NK activa-
tory receptors within the tumor microenvironment. qPCR 
was used to assess transcription of the NKG2D ligands and 
PVR within tumor tissue and adjacent uninvolved margin. 
Interestingly, expression of the NKG2D ligands ULBP2 and 
MICA was increased by 6.2 and 2.7 fold, respectively, within 
tumor tissue (ULBP2: 1000 & 162 for PDAC vs margin, 
p= .0059; MICA: 1510 vs 567 (p= .01) (Figure 6a)). PVR is 
aligand for DNAM and was markedly increased by 18-fold 
in the tumor microenvironment (4370 vs 245 (p= .0024) 
(Figure 6a)). Immunohistochemical analysis confirmed 
strong PVR, MICA, and ULBP2 expression on PDAC 
tumor tissue (Figure 6a).
To further understand how PDAC tumor cells might act to 
directly influence NK phenotype we next co-cultured primary 
PDAC cells with autologous PBMC-NK cells invitro. PDAC 
tumor organoids were generated and after 2–3 week matura-
tion were co-cultured with the PBMC for 14 days. NK cell 
Figure 5. Expression of activatory receptors is reduced substantially on NK cells within the PDAC tumor. The expression of differentiation markers including CD16, CD57, 
NKG2C(A) and activatory makers including DNAM-1. NKG2D, NKp30 (B) were compared between PBMCs and TILs from PDAC patients. The left panel of each marker is 
the histogram of representative examples to show the expression of each marker in PBMCs and TILs from PDAC patients. The comparison was carried out with 
percentage (middle panel) and mean florescence intensity (MFI) (right panel).The significance was determined using Wilcoxon matched-pairs signed rank test, p< .05(*), 
P< .01(**), p< .001(***) and p< .0001(****).
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phenotype was determined prior to incubation and then atday 
7 andday 14 following co-culture, the data were shown as 
relative percentage of surface expression compared to PBMC 
cultures without organoid (n = 3). CD16 and CD57 expression 
in the control group remained stable during culture but, inter-
estingly, CD16 expression was profoundly downregulated 
Figure 6. The PDAC tumor microenvironment expresses high levels of NK cell ligands and tumors induce downregulation of CD16 and CD57 on NK cells. (A): Total RNA 
from tumor tissues and normal margins were extracted and and reverse-transcripted to cDNA before the Q-PCR was performed to calculate absolute quantity of copy 
numbers using standard curve. The copy numbers per reaction were identified for 18s, ULBP2, MICA and PVR. The expression of PVR, MICA/B and ULBP2 in PDAC was 
demonstrated using the immunohistochemistry staining contrasting to normal adjacent pancreatic tissue. (B): The PDAC tumor organoids were generated through 3D 
culture. These pictures are representative organoids culture from day2, day4 and day 10 after the setup of the organoids. Right panel is the histogram of the EpCAM 
staining with the organoids culture after they were matured. (C): After the organoids culture was matured, the co-culture with the autologous PBMCs were set up. The 
phenotype of NK cells from the co-culture were monitored at day 7 and These flow dot plots represent the expression pattern of CD16 and CD56 of NK cells (CD3- and 
CD56+) from one experiment(left panel: before the co-culture, middle panel: day 7 post co-culture and right panel: day14 post co-culture). (D) The percentage of CD16, 
CD57, DNAM-1, NKG2D and NKp30 on NK population was compared before the co-culture, D7 and D14 post co-culture. Expression of each marker (D7 andD14) is shown 
as relative percentage on NK cells cultured with organoids compared with NK cells under control medium. The data was shown as using violin plot with each point 
represent a donor with significance was determined using Mann-Whitney testing, p < .05(*).
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during organoid co-culture, falling to 32% of the control group 
at day 14 (p= .01). As such the majority of NK cells came to 
develop aCD56dimCD16negative phenotype typical of those 
found in primary PDAC tumors (Figure 6c right panel). 
CD57 expression was also reduced during co-culture, falling 
to 37% of control values atday 14 (p= .12) (Figure 6d). This 
phenotypic change was not observed with organoid- 
conditioned medium. Expression of the activatory receptors 
DNAM-1, NKG2D and NKp30 expression was broadly stable 
during culture. As such tumor cells can rapidly directly down-
regulate CD16 and CD57 expression but do not modulate 
expression of activity ligands during short-term culture.
The CD56dim CD16neg NK population within blood does not 
affect overall survival but is positively correlated with 
tumor recurrence
Finally, we next assessed how the size and phenotype of 
the NK pool correlated with clinical outcome. 
Interestingly, the proportion of total NK cells within 
blood correlated directly with the size of the tumor 
(R = 0.38, P= .02). A trend toward reduced survival was 
also observed (Figure 7a).
Given our earlier observations on differential populations of 
CD56dimCD16neg NK within patients, and expansion after incuba-
tion with tumor organoids, we considered that these cells may be 
tumor-reactive and of particular interest. The cohort of PDAC 
patients undergoing potentially curative surgery was divided into 
two groups on the basis of the median percentage of 
CD56dimCD16neg NK cell populations (<1% and ≥ 1%) and corre-
lated with pathologic and clinical outcome (Table 1). Patients with 
≥ 1% CD56dimCD16neg NK cells had higher CA19-9 levels than 
those with <1% CD56dimCD16neg NK cells. The overall survival 
and disease-free survival curves were plotted using the Kaplan– 
Meier method and the significance was assessed using log-rank 
(Mantel-Cox) method. Patients with a CD56dimCD16neg NK popu-
lation higher than 1% of PBMCs demonstrated significantly 
reduced tumor recurrence (Figure 7b and Table 2) with amedian 
of disease-free survival of 451 days (164–737) compared with 
185 days (17–352) with those in the <1% group. These data indicate 
that CD56dimCD16neg NK populations may play acrucial role in 
containing recurrence of PDAC tumor after surgery.
Figure 7. The CD56dim CD16neg NK population within blood does not affect overall survival but is positively correlated with tumor recurrence. (A) Correlation between 
the percentage of total NK population in blood from PDAC patients with overall survival and tumor size was assessed. The line in the figure represents the linear 
regression line. In addition, the Spearman’s Rank correlation was used to test the significance and P value is indicated for each panel. (B) Kaplan-Meier curve (log-rank 
test) to compare the overall survival and disease free survival between two groups with different percentage of CD56dim CD16neg NK (cutoff point as median value 1%) 
from whole PBMCs. (C) Violin plot (Mann-Whitney test) to compare the percentage of CD56dim CD16neg NK cells in the patients who developed recurrent and who did 
not recurrent with significance was determined using Mann-Whitney testing, p < .05(*).
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Discussion
Most studies on the mechanisms of immune evasion in PDAC 
patients have focussed on T cell immune responses against 
tumor tissue but here we investigated NK cell phenotype and 
function. Differential features of NK cell immune evasion are 
observed within the tumor microenvironment and peripheral 
blood. As local invasion and metastasis ultimately develop in 
the majority of patients with PDAC, these findings indicate 
that immunotherapy protocols might seek to reverse these 
features in both settings.
A clear difference was apparent in the number of NK cells 
within the blood and tumor compartments. Lim et al have 
previously reported a higher percentage of NK cells in blood 
from PDAC patients compared to HD19 and a similar trend was 
seen in our study but did not reach statistical significance 
(Figure 1b). NK proportions were markedly lower within 
tumor tissue, representing only 3.5% of the TIL population. 
As such migration of NK cells into the tumor site is likely 
suppressed and lack of CXCR2 expression on NK cells has 
been shown to be one critical determinant.19 However, it should 
also be noted that NK cells numbers are frequently excluded 
from normal tissue and future work should address the profile 
of NK cells in control pancreatic tissue. The expression of CD16 
and CD57 also differed between compartments. This is likely to 
partially reflect differential NK phenotype within normal tissue 
and peripheral blood as NK cells within secondary lymphoid 
tissue express a CD56brightCD16neg phenotype30,32 whilst the 
cytotoxic CD56dimCD16pos subgroup predominates in 
blood.33,34 However, at least four NK subsets can be defined 
according to CD56 and CD16 expression30 and we show that 
NK cells with a CD56dimCD16neg phenotype are enriched 
within tumor but depleted within peripheral blood. This subset 
expresses a broadly immature phenotype with high expression 
of NKG2A+ and reduced CD57,35 findings that concur with our 
observations within NK-TIL. In contrast, NK cells in the blood 
of PDAC patients demonstrate a differentiated phenotype, with 
high levels of expression of CD16, CD57 expression. Organoid 
cultures provide an opportunity to interrogate interactions 
between primary tumor and immune effector cells in vitro and 
it was noteworthy that the features of NK cell phenotype within 
the tumor microenvironment were largely recapitulated follow-
ing culture with PDAC organoids, with substantial downregula-
tion of CD16 and CD57.
Downregulation of activating receptor expression on NK 
cells and impaired NK function is a common mechanism of 
immune evasion in cancer, and has been associated with 
tumor progression in PDAC.36–39 We also observed this pro-
file but it was noteworthy that a different pattern was 
observed on cells from blood or tumor microenvironment. 
NKG2D expression is often reduced on NK cells in cancer26,27 
and although modest downregulation was observed in PDAC 
patients this pattern remained stable within blood and TIL 
populations. In contrast, although NKp30 was only partially 
downregulated within blood, a profound reduction in expres-
sion was observed within tumor tissue. DNAM-1 expression 
was also selectively and comprehensively downregulated 
within the tumor microenvironment. Interestingly, expres-
sion of the inhibitory TIGIT receptor,40 which binds to the 
same ligands as DNAM-1, is significantly higher on NK cells 
from blood in PDAC patients compared with HD 
(Supplementary Figure 3) and reinforces an important role 
for this pathway. Another mechanism for impairment of NK 
cell function within the tumor microenvironment may be the 
conversion of NK cells into innate lymphoid cell due to high 
concentration of TGF-β.41.
The expression of ligands for NK activatory receptors was 
examined by PCR and immunohistochemistry. NKG2D ligand 
expression was increased in tumors, most notably for ULBP2 
and MICA which were increased by 2–6 fold. Interestingly, the 
concentration of serum NKG2D ligands is an independent mar-
ker of survival in PDAC42–45 and it most strongly associated with 
ULBP2.43 The expression of PVR, a major ligand for DNAM, 
was markedly increased on tumor cells (Figure 6a) and is likely 
to explain the profound downregulation of DNAM in this set-
ting. This is particularly noteworthy as DNAM-mediated cyto-
toxicity represents a major mechanism of lysis of PDAC cells.19
The functional profile of peripheral NK cells was assessed 
using cytotoxicity assay and cytokine profile after stimulation 
although too few cells were available within TIL for this ana-
lysis. One of the most striking observations was that NK cells 
from PDAC patients have a markedly altered profile of cyto-
kine production, with reduced levels of IFN-γ and IL-2 but 
substantially increased production of IL-10. As such they 
express a ‘regulatory’ phenotype, a concept that is emerging 
within NK biology. IL-10 producing NK cells have been 
demonstrated after stem cell transplantation46 and viral 
infection47 and likely mediate a regulatory role, promoted by 
Table 1. Demographic, diagnostic and therapeutic characteristics of two groups of 
PDAC patients with defined on the basis of CD56dim CD16neg NK cell population 
(<1% and ≥ 1%).
CD56dim CD16neg NK cells
NK low (<1) 
n = 16
NK high (1+) 
n = 14 p
Age 67 (61–75) 75 (65–79) 0.525
BMI 27.3 (25.1–29) 26.9 (23.6 − 28.8) 0.856
Gender (male) 10 (63%) 6 (43%) 0.272
Smoker (yes) 3 (19%) 3 (21%) 1
Preoperative biliary drainage 
(Yes)
4 (25%) 2 (14%) 0.651
Jaundice at presentation (yes) 15 (94%) 13 (93%) 1
Vit D 25 (11.5–27.25) 31 (26–39) 0.9
CA19-9 109 (11–459) 625 (156–3036) 0.041
Neoadjuvant therapy (yes) 1 (6%) 1 (7%) 1
Resected at surgery (yes) 13 (81%) 13 (93%) 0.602
T stage 1 2 3 3 10 3 2 10 1 0.701
N Stage 0/1/2 2 7 5 3 7 3 0.775
Positive resection margin (yes) 7 (44%) 7 (50%) 1
Tumor size (mm) 25 (22.75–28.75) 25 (25–35) 0.223
Lymph node ratio 0.23 (0.13–0.53) 0.09 (0.04–0.43) 0.395
Comprehensive complication 
index
4.5 (0–17.9) 21 (0–26) 0.553
Adjuvant therapy (yes) 10 (62.5%) 12 (86%) 0.093
Palliative therapy (yes) 8 (50%) 5 (35%) 0.464
Table 2. Clinical survival of two groups of PDAC patients with defined on the basis 
of CD56dim CD16neg NK cell population (<1% and ≥ 1%).
CD56dim CD16neg NK cells NK low (<1) n = 16 NK high (1+) n = 14 p
OS median (95% CI) 409 (383–434) 499 (276–718) 0.751
DSS median (95% CI) 405 (360–449) 487 (173–800) 0.853
DFS median (95% CI) 185 (17–352) 451 (164–737) 0.033
e1845424-10 F. MARCON ET AL.
sustained proliferation after chronic stimulation.47,48 CD56bri 
NK cells are generally regarded as the major subset of cytokine- 
producing cells49 but CD56dim cells may also display rapid 
cytokine production after stimulation,50 particularly from the 
CD16neg subset.35
These findings raise questions as to how IL-10 production 
might act to suppress tumor-specific immune responses. 
Systemic concentrations of IL-10 levels are 3–5 fold higher in 
the blood of patients with PDAC, where they are strongly 
correlated with impaired T cell function,11–13 and our data 
indicate that NK cells are likely to be a major source of IL-10 
production within the periphery. IL-10 might also have a direct 
impact on NK cell function and has been shown to inhibit NK- 
92 killing of PDAC cells in vitro. Importantly, this effect was 
restored by anti-IL-10 receptor blockade, indicating a potential 
novel therapeutic intervention.51 Of note, all patients studied had 
undergone operative resection of PDAC with curative intent and 
had no evidence of metastatic disease at this time. Despite this, 
our findings reveal that the peripheral immune system is already 
significantly modulated by the disease process and it is likely that 
this immunoregulatory environment may play an important part 
in tumor spread. Indeed the number of peripheral NK cells has 
been identified as an independent marker of increased survival.20
Interestingly, a positive correlation between the percentage 
of peripheral NK cells and the size of the PDAC tumor. The 
reasons underlying this are not clear but may include direct 
tumor-mediated stimulation of NK proliferation or increased 
partitioning of the NK pool from the tumor and into the 
peripheral circulation. The CD56dimCD16neg NK cell subpo-
pulation was of particular note as it was reduced within blood 
but enriched in TILs. Interestingly, patients with peripheral 
CD56dimCD16neg NK populations above the median level 
(>1%) suffered less disease recurrence than patients with 
<1%. Our observation that this subset can be expanded by co- 
culture with autologous organoids reveals a potential mechan-
ism for therapeutic intervention.
Our findings indicate that a range of mechanisms of immune 
evasion are apparent within NK cells in patients with PDAC. These 
include exclusion from the tumor site, downregulation of activatory 
receptors with impaired differentiation in the tumor microenvir-
onment, and promotion of an immunoregulatory IL-10 phenotype 
within the periphery. This suggests that primary NK cells might 
have potent activity to suppress PDAC development and that these 
evasion mechanisms are a necessary component of tumor evolu-
tion. As such, approaches that overcome these mechanisms could 
have considerable potential in a disease with few therapeutic 
options. Approaches such as IL-10 blockade, mechanisms to sup-
port activatory receptor expression52, or NK cellular therapy all 
represent options for future investigation.
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